Highly connected, non-redundant microRNA functional control in breast cancer molecular subtypes

Guillermo de Anda-Jáuregui1,2,3, Jesús Espinal-Enríquez1,3, Enrique Hernández-Lemus1,3

  • 1Computational Genomics, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.

Interface Focus
|June 14, 2021
PubMed

Insights

Commodore microRNAs (cdre-miRs) were identified in breast cancer subtypes using network biology. These cdre-miRs link to distinct genes and cancer hallmarks, suggesting potential therapeutic targets.

Area of Science:

  • Genomics and Bioinformatics
  • Molecular Biology
  • Cancer Research

Background:

  • Breast cancer exhibits significant molecular and phenotypic heterogeneity, influencing transcriptional regulatory programs.
  • Network biology, specifically gene co-expression networks, helps elucidate abnormal gene regulation and breast cancer subtypes.
  • MicroRNAs (miRs) are crucial in regulating normal and aberrant transcription processes.

Purpose of the Study:

  • To reconstruct miR-gene co-expression networks for distinct breast cancer molecular subtypes.
  • To identify potential control elements, defined as Commodore miRs (cdre-miRs), within these networks.
  • To associate identified cdre-miRs with specific biological functions and cancer hallmarks.

Main Methods:

  • Reconstruction of miR-gene co-expression networks using high-throughput data from 424 Cancer Genome Atlas (TCGA) samples.
  • Identification of cdre-miRs based on network connectivity and redundancy within each molecular subtype.
  • Systematic literature validation to associate cdre-miRs with biological functions and cancer hallmarks.

Main Results:

  • cdre-miRs were identified in three out of four analyzed breast cancer molecular subtypes.
  • Each identified cdre-miR was uniquely linked to a distinct set of genes and biological functions specific to its subtype.
  • Associated biological functions included key cancer hallmarks: angiogenesis, cell adhesion, cell cycle, and apoptosis regulation.

Conclusions:

  • Network biology approaches effectively identify subtype-specific regulatory elements like cdre-miRs in breast cancer.
  • cdre-miRs are associated with critical cancer hallmarks, highlighting their potential role in disease progression.
  • Further functional studies are needed to determine the therapeutic relevance of these cdre-miRs as actionable targets.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K